13F Portfolios

Vestal Point Capital, LP — APOGEE THERAPEUTICS INC APGE: Quarterly 13F Position History

Vestal Point Capital, LP has reported APOGEE THERAPEUTICS INC (APGE) on 7 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2024. As of Q1 2026, the position is sized at 1,100,000 shares ($92.6M market value, 2.59% of the equity book). Quarter-over-quarter share count change: + 550,000 (+100.0%) .

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 7 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 1,100,000 +550,000 +100.0% $92.6M 2.59% $84.17
Q4 2025 550,000 +125,000 +29.4% $41.5M 1.52% $75.48
Q3 2025 425,000 +425,000 $16.9M 0.77% $39.73
Q2 2025 0 0 $0 0.00%
Q1 2025 0 0 $0 0.00%
Q4 2024 0 136,500 -100.0% $0 0.00%
Q3 2024 136,500 $8.0M 0.63% $58.74

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Vestal Point Capital, LP first disclose a APGE position in 13F-HR filings?

Vestal Point Capital, LP first reported APOGEE THERAPEUTICS INC (APGE) on its 13F-HR filing for the period ending 2024-09-30 (Q3 2024). The position has appeared on 7 reported quarters within Pactolio's tracked window.

What was Vestal Point Capital, LP's most recent quarter-over-quarter share-count change in APGE?

Between Q4 2025 and Q1 2026, Vestal Point Capital, LP added 550,000 shares of APGE (+100.0%), bringing the total reported position to 1,100,000 shares at a market value of $92.6M.

Does the implied price-per-share represent Vestal Point Capital, LP's cost basis in APGE?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.